Concepedia

Terence O’Reilly

TO

Statistics

Publications

29

Citations

3.2K

H-Index

22

Active since

1995

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

Basilea Pharmaceutica (Switzerland)

Friedrich Miescher Institute

University Hospital of Zurich

Terence O’Reilly is an author at Novartis (Switzerland) specializing in pharmacology, medicine, and oncology.

Publications per year

1995–2015

29

Publications

29

The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation

Iwan Beuvink, Anne Boulay, Stefano Fumagalli et al. · Cell · 2005 · 490 citations · Full text

, , +14

Dual Inhibition of mTOR and Estrogen Receptor Signaling<i>In vitro</i>Induces Cell Death in Models of Breast Cancer

Anne Boulay, Joëlle Rudloff, Jingjing Ye et al. · Clinical Cancer Research · 2005 · 335 citations · Full text

, , +17

Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells

Anne Boulay, Sabine Zumstein-Mecker, Christine Stephan et al. · Cancer Research · 2004 · 319 citations · Full text

, , +14

Antagonism of Sphingosine-1-Phosphate Receptors by FTY720 Inhibits Angiogenesis and Tumor Vascularization

Kenneth R. LaMontagne, Amanda Littlewood‐Evans, Christian Schnell et al. · Cancer Research · 2006 · 298 citations

, , +17

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

Heidi A. Lane, Jeanette M. Wood, Paul M.J. McSheehy et al. · Clinical Cancer Research · 2009 · 251 citations · Full text

, , +17

1–5 of 29